Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. More Details
+ 2 more risks
Excellent balance sheet and overvalued.
Share Price & News
How has Plus Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PSTV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: PSTV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: PSTV exceeded the US Biotechs industry which returned 25.3% over the past year.
Return vs Market: PSTV underperformed the US Market which returned 51.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Plus Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StIs Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
5 months ago | Simply Wall StIs Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
7 months ago | Simply Wall StHow Much Does Plus Therapeutics' (NASDAQ:PSTV) CEO Make?
Is Plus Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PSTV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PSTV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PSTV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PSTV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PSTV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PSTV is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (3.4x).
How is Plus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSTV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PSTV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PSTV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PSTV is forecast to have no revenue next year.
High Growth Revenue: PSTV is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PSTV's Return on Equity is forecast to be high in 3 years time
How has Plus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PSTV is currently unprofitable.
Growing Profit Margin: PSTV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PSTV is unprofitable, but has reduced losses over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare PSTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: PSTV has a negative Return on Equity (-103.79%), as it is currently unprofitable.
How is Plus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PSTV's short term assets ($15.4M) exceed its short term liabilities ($8.3M).
Long Term Liabilities: PSTV's short term assets ($15.4M) exceed its long term liabilities ($508.0K).
Debt to Equity History and Analysis
Debt Level: PSTV's debt to equity ratio (68.2%) is considered high.
Reducing Debt: PSTV's debt to equity ratio has reduced from 215.2% to 68.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PSTV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PSTV has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 22.1% each year.
What is Plus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PSTV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PSTV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PSTV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PSTV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PSTV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Hedrick (57 yo)
Dr. Marc H. Hedrick, M.D. has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedric...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD532.73K).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
Experienced Management: PSTV's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: PSTV's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PSTV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 443.9%.
Plus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Plus Therapeutics, Inc.
- Ticker: PSTV
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$47.700m
- Shares outstanding: 21.11m
- Website: https://www.plustherapeutics.com
Number of Employees
- Plus Therapeutics, Inc.
- 4200 Marathon Boulevard
- Suite 200
- United States
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug can...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 05:13|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.